Chronic inflammatory demyelinating polyneuropathy (CIDP) is a form of chronic neuropathy characterized by demyelination due to immune-mediated processes. In addition to the typical form of CIDP, several atypical forms, such as multifocal acquired demyelinating sensory and motor, distal acquired demyelinating symmetric (DADS), pure sensory, pure motor, and focal types, have also been included as subtypes of CIDP, indicating the heterogeneity of pathogenesis. The degradation of the myelin sheath by macrophages has been reported in CIDP and is considered to play an important role in the pathogenesis of this disease. By contrast, recent studies have suggested the association of autoantibodies directed against paranodal junction proteins, such as anti-neurofascin 155 and anti-contactin 1 antibodies, with subpopulations of CIDP patients. Although patients with these antibodies tend to manifest typical CIDP or DADS symptoms, such patients show unique clinical characteristics, such as a younger age at onset, sensory ataxia, tremor and poor response to intravenous immunoglobulin treatment. Classical macrophageinduced demyelination is not observed in patients with these antibodies, whereas paranodal dissection resulting from attachment of immunoglobulin G4 antibodies to paranodal junctions plays a pivotal role in the mechanisms of neuropathy. Therefore, two distinct mechanisms exist that lead to nerve conduction abnormalities from a pathological viewpoint in CIDP. Advances in the search for autoantibodies in CIDP might make it necessary to reconsider the classification of this disease from the viewpoint of antibody recognition sites.
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a form of chronic neuropathy characterized by demyelination due to immune-mediated processes. [1] [2] [3] [4] [5] [6] [7] [8] The typical form of CIDP is defined as neuropathy with chronically progressive, stepwise or recurrent symmetrical proximal and distal weakness and sensory dysfunction in all extremities that develops over at least 2 months. 9 Although less common than so-called typical CIDP, atypical forms, such as multifocal acquired demyelinating sensory and motor, distal acquired demyelinating symmetric (DADS), pure sensory, pure motor, and focal types, have also been considered subtypes of CIDP. 9, 10 The diversity of clinical features and response to treatment indicate that the pathogenesis of CIDP is heterogeneous, involving both cell-mediated and humoral immunities. 6 Electrophysiological findings suggestive of demyelination are essential for the diagnosis of CIDP, while pathological evidence has been considered a supportive criterion in clinical practice. 9 The degradation of the myelin sheath by macrophages that have infiltrated into the endoneurium has been reported in CIDP, and has been thought to play an important role in the pathogenesis of this disease. 1, 5, 7, 11, 12 Although this macrophage-induced demyelination has been regarded as the pathological hallmark, not all nerve biopsy specimens taken from patients with CIDP have shown this type of classical demyelination. 11, 13 Recent studies have suggested the association of autoantibodies directed against paranodal junction proteins, such as anti-neurofascin 155 and anti-contactin 1 antibodies, with subpopulations of CIDP patients. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Clinically, patients with these antibodies tend to manifest typical CIDP or DADS. However, these patients show pathological features distinct from those that are represented in classical macrophage-induced demyelination.
Here, we describe two distinct pathological features observed in patients with CIDP. The first is the classical macrophage-induced demyelination, and the second is paranodal dissection induced by autoantibodies to paranodal junction proteins. This advance in the search for autoantibodies in CIDP might make it necessary to reconsider the classification of this disease from the viewpoint of antibodyrecognition sites.
Classical concept of CIDP with macrophage-induced demyelination
Demyelination caused by macrophages has been considered to play a pivotal role in the pathogenesis of CIDP. An early report of the pathological features of CIDP included serous edema, infiltration of mononuclear cells without evidence of vasculitis, macrophage-induced segmental demyelination and hypertrophic changes. 1 A subsequent report also showed detailed macrophage behaviors using electron microscopic observation of nerve biopsy specimens.
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That study examined 23 patients who manifested subacute or relapsing demyelinating polyneuropathy, likely identical to CIDP, and found active demyelinating changes in six nerve biopsy specimens from five patients. This active demyelination was found in all examined fascicles in five specimens, and was limited to a single fascicle in one specimen. In the affected fascicles, the authors observed macrophages containing myelin debris, and lymphocytes were seen. These reports have proposed the importance of macrophages in the process of demyelination in patients with CIDP. Reflecting the chronic process of this disease, various stages of this macrophage-mediated demyelination are found in a single specimen (Fig. 1) .
Myelin breakdown seems to be initiated by macrophages breaching the basement membranes that normally surround the myelinated fibers (Fig. 2) . Then, macrophages invade the inner space within the basement membrane of myelinated fibers and surround the outermost layer of myelin. Cytoplasmic processes that extend from adjacent macrophages then strip superficial myelin lamellae away from the myelin sheath (Fig. 3) . These cytoplasmic processes extend through the space between major dense lines. The surface of myelin adjacent to the cytoplasm of macrophages becomes fuzzy as a result of the disruption of myelin lamellae. Disrupted major dense lines terminate as small dark swellings. Destructed myelin is ingested by macrophages and degraded as small myelin debris.
After the disappearance of macrophages from the inner space of the basement membrane, findings suggestive of the formation of onion bulbs are observed. 11 The demyelinated axons show a wrinkled axolemma, and densely packed neurofilaments and microtubules. The residual Schwann cell cytoplasm, which tends to appear pale, persists around the demyelinated axon until the initiation of remyelination by another dense Schwann cell cytoplasm rich in granular endoplasmic reticulum. This new Schwann cell cytoplasm envelops the axon and displaces the residual pale Schwann cell cytoplasm. As a result, a detachment of the residual pale Schwann cell cytoplasm occurs, forming the unique onion bulb configurations that surround the axon (Fig. 4) . Only one or two layers of flattened Schwann cell cytoplasmic processes may surround the axon in the early phase of neuropathy. However, some of the patients might show extensive formation of onion bulbs with multiple layers of flattened processes, resulting in marked enlargement of the endoneurial area. 24 Do all patients with CIDP show macrophageinduced demyelination?
The aforementioned ultrastructural analyses strongly indicate that macrophages play a pivotal role in the demyelination and subsequent onion bulb formation in patients with CIDP. Other reports have corroborated this view by showing macrophage-induced demyelination by transverse sections of epoxy resin-embedded specimens or teased-fiber preparations. 5, 7, 12, 25 However, not all patients show so-called macrophage-induced demyelination in nerve biopsy specimens. Actually, Prineas and McLeod found such active demyelination in just six of 26 nerves. 11 We examined the presence of macrophageinduced demyelination in sural nerve biopsy specimens from 23 patients with CIDP. 13 Nine of these patients tested positive for anti-neurofascin 155 antibodies, and another patient had anti-contactin 1 antibodies. As described later, neurofascin 155 and anti-contactin 1 are located at the paranode to connect terminal loops of myelin to the axolemma, and antibodies directed against these proteins cause neuropathy unrelated to myelin damage induced by macrophages. 13 In the other 13 patients without these antibodies, electron microscopic examination revealed the degradation of the myelin sheath by macrophages in four patients (3/4 typical CIDP patients and 1/3 DADS neuropathy patients). Onion bulbs were observed in three additional patients, although macrophages were not found.
Teased-fiber preparations might also show fibers with demyelination induced by macrophages. 25 In our study, seven of the aforementioned 13 antibody-negative patients showed fibers with a classical feature of long segmental demyelination indicative of CIDP. 13 Bouchard et al. reported that teased-fiber preparations of the 95 nerve biopsy specimens showed purely demyelinating lesions in 68 patients, mixed axonal and demyelinating lesions in 20 patients, predominantly axonal lesions in five patients, and normal findings in two patients. 4 In that study, active demyelinating lesions, defined as macrophagemediated demyelination, debris-laden macrophages in the endoneurium or complete demyelination of fibers without any evidence of remyelination, were found in 25 nerve specimens. The authors also found one or more onion bulb formations per microscopic field at 9630 magnification in 17 patients.
Note that segmental demyelination in teased-fiber preparations is not necessarily caused by phagocytosis of myelin by macrophages. For example, patients with anti-myelin-associated glycoprotein (MAG) antibodies show extensive demyelination unrelated to macrophages. 26 Deposition of anti-MAG antibodies causes a detachment of paranodal myelin terminal loops, resulting in segmental demyelination in this type of neuropathy. Patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome also show segmental demyelination unrelated to macrophages predominantly in the small myelinated fibers. 27 Furthermore, patients with pure axonal neuropathy, such as alcoholic neuropathy, might also show widening of the consecutive nodes of Ranvier in a single teased fiber as a result of axonal atrophy (i.e. secondary demyelination). 28 
CIDP with autoantibodies to nodal and paranodal components
Recent studies have suggested the association of autoantibodies directed against nodal and paranodal components with subpopulations of CIDP Figure 3 A macrophage stripping myelin lamellae. Stripping of superficial myelin lamellae away from the myelin sheath occurs through a cytoplasmic macrophage process that extends from adjacent macrophage cytoplasm (arrow). These cytoplasmic processes of macrophages extend through the spaces between adjacent major dense lines. The surface of myelin adjacent to the cytoplasm of macrophages becomes fuzzy as a result of the disruption of myelin lamellae (black arrowheads). Disrupted major dense lines terminate as small dark swellings (white arrowheads). The asterisk indicates an axon. Longitudinal section of a sural nerve biopsy specimen. Uranyl acetate and lead citrate stain. Scale bar, 0.2 lm.
patients. [29] [30] [31] [32] Among these autoantibodies, those directed against paranodal junction proteins, such as anti-neurofascin 155 and anti-contactin 1 antibodies, have been found in a subpopulation of patients with characteristic clinical features. [13] [14] [15] [16] [18] [19] [20] 22, 23 Patients with these antibodies tend to be younger at the age at onset, and show sensory ataxia and tremor. 13, 16, 17, 19, 20, 22, 23 We examined anti-neurofascin 155 and anti-contactin 1 antibodies using sera obtained from 131 patients with CIDP. 13 Nine of 10 patients (patients 1-9) tested positive for antineurofascin 155 antibodies, and another 72-year-old male patient (patient 10) tested positive for anticontactin 1 antibodies. The diagnosis of CIDP was based on diagnostic criteria of the European Federation of Neurological Societies/Peripheral Nerve Society. 9 According to these criteria, these 10 patients could be divided into four patients with typical CIDP and six patients (including the case with anti-contactin 1 antibodies) with DADS neuropathy. In general, intravenous immunoglobulin, corticosteroids, and plasma exchange are the first-line treatments for CIDP. 5, 9, 33 However, patients with anti-neurofascin 155 and anti-contactin 1 antibodies tend to be unresponsive to intravenous immunoglobulin. 16, 17, 19, 20, 22, 23 As some of the patients with these antibodies are refractory to immunotherapies, attempts to apply alternative therapies, such as rituximab, rather than conventional first-line treatments, have also been reported. 34 Note that the immunoglobulin G (IgG) subclass of anti-neurofascin 155 and anti-contactin 1 antibodies is predominantly IgG4. 13, 17, 19, 20, 22, 23 Thus, immunoadsorption plasmapheresis with tryptophan columns, which is not suitable for removing IgG4, should not be used to treat patients with these antibodies. 35 Pathological characteristics of CIDP with antibodies against paranodal junction components by conventional observation
As the number of reports regarding antibodies against paranodal junction proteins has increased, the chances to examine pathological findings in patients with these antibodies have also increased. Ogata et al. reported light microscopic findings of the transverse sections of sural nerve biopsy specimens from two patients with anti-neurofascin 155 antibody-positive CIDP. 20 The findings were summarized as subperineurial edema, reduction of myelinated fiber density, paranodal demyelination and the absence of onion bulbs or inflammatory cells. Another subsequent report provided light microscopic photographs of the transverse sections of the sural nerve taken from two other CIDP patients with anti-neurofascin 155 antibodies that also suggested similar pathological features. 22 Three sural nerve biopsy specimens taken from CIDP patients with anti-contactin 1 antibodies showed similar pathological features. 18 We also examined sural nerve biopsy specimens obtained from nine patients with antineurofascin 155 antibodies and one patient with anti-contactin 1 antibodies, and we found endoneurial edema, a slight reduction of myelinated fiber density with scattered myelin ovoids, and the absence of macrophage-mediated demyelination or onion bulbs. 13 Although the findings were suggestive of the degeneration of myelinated fibers, the unmyelinated fibers were well preserved. 13 The light microscopic observations suggested that the classical macrophage-induced demyelinating process that has been reported in CIDP does not seem to participate in the mechanisms of CIDP with these antibodies. As the major subclass of immunoglobulin of anti-neurofascin 155 and anti-contactin 1 antibodies is IgG4, 13, 17, 19, 20, 22, 23 deposition of these antibodies might not provoke inflammatory processes. 13 Actually, deposition of complements at sites of IgG4 deposition was not detected by immunofluorescent studies using longitudinal fresh-frozen sections of biopsied sural nerve from patients with these antibodies. 13 These results prompt the question: what is the mechanism resulting in conduction abnormalities in CIDP patients with antibodies to paranodal junction proteins?
Paranodal dissection caused by IgG4 antibodies
Immunofluorescence studies have shown that IgG4 antibodies directed against anti-neurofascin 155 and anti-contactin 1 antibodies deposit at paranodes in CIDP patients with these antibodies. 13 However, the deposition of IgG4 at paranodes in these patients does not trigger inflammatory responses, such as the activation of complement pathways reported in anti-MAG neuropathy. 13, 26 Thus, direct morphological observation of paranodal structures is required to elucidate the role of IgG4 antibodies relating to paranodal junction proteins. In this context, assessment of fine paranodal structures using longitudinal sections by electron microscopy is suitable to detect the initial lesion resulting from the deposition of these antibodies. Three studies to date, including ours, have addressed the fine structure of paranodes from this viewpoint. 13, 35, 36 Vallat et al. examined paranodal structures in two patients with anti-neurofascin 155 antibody-positive CIDP and compared them with those in four patients without these antibodies, three normal control individuals and five patients with other neuropathies. 36 The authors found a loss of transverse bands that link myelin terminal loops to axolemma in anti-neurofascin 155 antibody-positive CIDP patients. Abnormal cellular processes that penetrated into the expanded spaces between the paranodal myelin loops and the axolemma were also shown. Kuwahara et al. also reported a loss of transverse bands in four patients with anti-neurofascin 155 antibody-positive CIDP. 35 Our study included nine patients with anti-neurofascin 155 antibodies and one patient with anti-contactin 1 antibodies; we compared these patients with 13 CIDP patients without these antibodies, identifying a wide space between myelin terminal loops and axolemma, called paranodal dissection, in antibody-positive patients, but not in antibody-negative patients.
Regarding anti-neurofascin 155 antibody-positive CIDP, a recent review article also provided a photograph showing a loss of transverse bands between myelin terminal loops and axolemma, which is similar to the results of other studies. 37 According to our study, the detachment of myelin terminal loops from axolemma seems to be frequent at the portion of paranode close to the node of Ranvier in anti-neurofascin antibody-positive patients. We observed occasional large spaces between the terminal loops and axolemma (Fig. 5) . However, the extent of detachment was usually mild at terminal loops in the outermost layers of the myelin sheath of such paranodes, and we did not observe any extreme dislocation of terminal loops leading to peeling off and exposure of axons (i.e. demyelination), which has been reported in neuropathy with anti-MAG antibodies. 26 Similar axo-glial detachment was also found in a patient with anti-contactin 1 antibodies, and it occurred predominantly at terminal loops adjacent to nodes of Ranvier. In contrast to characteristic morphological changes at the paranode, changes at internodes were unremarkable. 13 Although uncompacted myelin lamellae were observed in three of nine patients with anti-neurofascin 155 antibodies in our study, six of 13 antibody-negative patients also showed similar findings.
Specificity of paranodal dissection
Normally, the terminal loops of myelin lamellae closely appose the axolemma at the paranode (Fig. 6a) . 13 Electron-dense regions (i.e. transverse bands) exist between the terminal loops and axolemma, suggesting that these regions are tightly connected to each other. In animal models deficient of neurofascin 155 and contactin 1, a loss of transverse bands between myelin terminal loops and axolemma, despite their close apposition, has been reported. 38, 39 This finding is reasonable, because neurofascin 155 and contactin 1 are present at paranodal junctions, and act to attach myelin terminal loops to the axolemma. 30, 40 Loss of transverse bands has been reported in a rat model of diabetic neuropathy, suggesting that such abnormalities of paranodal axo-glial junctions might also be observable with the other diseases. 41 Giannini and Dyck showed a photograph demonstrating a small space between myelin terminal loops and the axolemma taken from a sural nerve of a patient with CIDP in 1996 when antibodies to paranodal junction proteins were not yet well known in the context of CIDP. 42 We have also found small spaces devoid of transverse bands between paranodal terminal loops and axolemma in CIDP patients without antibodies to paranodal junction proteins, although the frequency was low (Fig. 6b) . 13 However, such
(b) Figure 6 Normal paranodal structure and loss of transverse bands in a chronic inflammatory demyelinating polyneuropathy patient without antibodies to paranodal junction proteins. (a) Normally, the terminal loops of myelin lamellae are closely apposed to the axolemma at the paranode. Electrondense regions (i.e. transverse bands) exist between the terminal loops and the axolemma (arrows), suggesting that these components are tightly connected. (b) Loss of transverse bands between paranodal terminal loops and the axolemma can be observed in chronic inflammatory demyelinating polyneuropathy patients without antibodies to paranodal junction proteins. However, such space is typically small, <20 nm, in antibody-negative chronic inflammatory demyelinating polyneuropathy patients. Longitudinal section of a sural nerve biopsy specimen. Uranyl acetate and lead citrate stain. Scale bars, 0.2 lm.
spaces were typically small, <20 nm, in antibodynegative CIDP patients. Such small spaces were often found in fibers with thin myelin, indicative of remyelination, and seemed to be unrelated to demyelination defined as the widening of the node of Ranvier. 13 Therefore, a small space of <20 nm between myelin terminal loops and axolemma resulting from a loss of transverse bands is not a specific feature in patients with antibodies to paranodal junction proteins. By contrast, a large space of ≥20 nm resulting in paranodal dissection might be a more specific finding caused by IgG4 antibodies to paranodal junction proteins.
Distinct mechanisms of neuropathy caused by IgG4 antibodies against paranodal junction components
Electrophysiological evidence showing nerve conduction abnormalities is an essential feature in CIDP. Myelinated fibers of the peripheral nervous system are divided structurally into four domains along the axon, consisting of the node of Ranvier, the paranode, the juxtaparanode and the internode. 43 The node of Ranvier is the site where action potentials are generated to sustain saltatory conduction, while the paranode plays a role as an insulant. 29, 30 Thus, the structures of the nodes of Ranvier and paranodes are essential for maintaining normal nerve conduction. Defects in myelin (i.e. demyelination) resulting from degradation of myelin by macrophages might be the classical causal example regarding nerve conduction abnormalities in patients with CIDP. 1, 5, 7, 11, 12 By contrast, completely different factors seem to be active in the mechanisms of conduction abnormalities of patients with IgG4 antibodies against paranodal junction proteins, such as neurofascin 155 and contactin 1. 13 An attachment of IgG4 at paranodal junctions might be the first process of abnormal nerve conduction in these patients. Passive transfer of antibodies against paranodal junction proteins induced conduction block. 44 However, this model did not show slowing of nerve conduction indices, which is ubiquitously observed in patients with antibodies to paranodal junction proteins. 13, 20, 23 Taking into account the shorter duration of exposure to antibodies in animal models relative to that in patients, this conduction block might represent a functional deficit unaccompanied by significant morphological abnormalities. 45 As the duration of exposure to antibodies becomes longer, refractory morphological abnormalities, including paranodal dissection, may occur, resulting in additional abnormalities of conduction indices, such as the slowing of nerve conduction velocities and prolongation of distal latencies. 45 In addition to the role in saltatory conduction, the structures of the nodes of Ranvier and paranodes are also important for axon-Schwann cell interactions to maintain axons. 43 Therefore, paranodal dissection might induce axonal damage. Although demyelination is detected in some of the patients with antineurofascin 155 and anti-contactin 1 antibodies, the cause of this demyelination seems to be different from that caused by macrophages. 13 In patients with these antibodies, segmental demyelination was detected as the widening of the consecutive nodes of Ranvier in a single teased fiber. 13 Similar widening of the consecutive nodes of Ranvier in a single fiber has also been reported in patients with pure axonal neuropathy, such as alcoholic neuropathy. 28 Thus, demyelination found in patients with these antibodies might be, at least in part, a secondary change related to axonal damage.
Conclusion
In addition to the typical form of CIDP, atypical forms, such as multifocal acquired demyelinating sensory and motor, DADS, pure sensory, pure motor, and focal types, have also been included as subtypes of CIDP, indicating the heterogeneity of pathogenesis. Although demyelination caused by macrophages has been considered to play a pivotal role in the pathogenesis of CIDP, not all patients show such macrophage-induced demyelination. Recent studies have suggested the association of autoantibodies with paranodal axo-glial junction proteins, such as antineurofascin 155 and anti-contactin 1 antibodies, in a subpopulation of CIDP patients. Paranodal dissection and the absence of classical macrophage-induced demyelination were the characteristic features in these patients. Thus, there are at least two distinct mechanisms of neuropathy in CIDP from a pathological viewpoint. The advances in the search for autoantibodies, particularly those directed against paranodal junction proteins, in CIDP create a need to reconsider the classification of this disease from the viewpoint of antibody recognition sites. By contrast, the association between macrophage-induced demyelination and autoantibodies has not been identified. Further studies are required to elucidate the immunological process regarding the participation of macrophages in CIDP.
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